Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatrician

Ticker(s): SNY, AZN

Who's the expert?

Institution: New York-Presbyterian Hospital and New York Hotel Trades Commission

Pediatrician for 31 years who currently treats 40 patients with ADHD
Graduated from Athens Medical School; Pediatric Residency at NYU
Specializes in infectious disease

Interview Goal

This interview will focus on the recent FDA approval of Nirsevimab as an RSV preventative option for the broad newborn and infant population.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.